Abstract. The McCune-Albright syndrome (MAS) is characterized by a triad of poly/monostotic fibrous dysplasia, café-au-lait macules and hyperfunctioning endocrinopathies including growth hormone (GH) excess. Polyostotic bone lesions and café-au-lait macules are common while monostotic bone lesions are rare. Similarly, acromegaly as a manifestation of endocrine hyperfunction with MAS is uncommon and in most of the instances somatotropinoma has not been documented. We report 3 patients, two of them had monostotic lesion, none had café-au-lait macules and all had GH secreting pituitary macroadenoma. All of them underwent transfrontal pituitary adenomectomy and had histopathological confirmation of GH secreting pituitary adenoma. A brief review of literature is also presented.
THE original description of McCune-Albright syndrome (MAS) included osteitis fibrosa dissemina, café-au-lait macules and precocious puberty [1, 2] . Polyostotic fibrous dysplasia and café-au-lait macules are invariably present while monostotic lesions are less common [3] . Endocrine hyperfunction other than precocious puberty in association with MAS include hyperthyroidism, hypercortisolism, hypersomatotropism and hypophosphatemic rickets [1] [2] [3] . Association of MAS with hypersomatotropism is rare, and pituitary adenoma is demonstrable in only 40-50% of these patients [3, 4] . Till 2002, only 51 cases of MAS with acromegaly have been reported in English literature 34] . However, pathological examination of the pituitary either at surgery or necropsy has been reported in only 8 of them [3, 6, 7, 10, 14, 24, 28, 30] . We report 3 patients, in the existing repertoire of this rare entity, who had fibrous dysplasia and acromegaly due to growth hormone (GH) secreting pituitary adenoma.
Case Studies

Case 1
A 28-year-old man presented with progressive increase in height, acral enlargement and coarse and asymmetrical facial features from the age of 10 years. He gave no history of headache, visual field loss, symptoms of raised intracranial tension or features of any endocrine deficiencies or hyperfunctions other than GH excess. Initiation and development of his secondary sex features were normal. On examination, his height was 212 cm, weight 120 kg, body mass index (BMI) 27.2 Kg/m 2 and BP 150/90 mmHg. He had facial asymmetry with coarse features and acral enlargement with excessive sweating but no café-au-lait macules, bony swelling or goitre. Systemic examination and pubertal maturation indices (A 3 , P 6 , testicular volume 25 ml bilateral) were normal.
On investigation, basal GH was 86 ng/ml that paradoxically rose to 130 ng/ml (N<2 ng/ml) following 75 gm oral glucose load. In response to 100 mg IV bolus thyrotropin releasing hormone (TRH), GH increased from 84 ng/ml to 218 ng/ml. Serum PRL was 500 mIU/L (N, 150-600 mIU/L), T 3 1.2 ng/ml (N, 0.6-1.5), T 4 70 ng/ml (N, 60-150), cortisol at 8 am 400 nmol/L (N, 300-500) and at 4 pm 270 nmol/L (N, 200-400), LH 2.6 IU/L (N, 5-15), FSH 3.2 IU/L (N, 5-15) and testosterone 6 nmol/L (N, 9-27). X-ray skull showed sellar enlargement with destruction of clinoid process and radiodense lesions in left nasal cavity and paranasal sinuses with thickening of base of the skull (Fig. 1a) . Long bones and pelvic girdle X-ray did not reveal any abnormalities. Contrast enhanced computerized tomography (CECT) of head revealed lesions with ground glass appearance in paranasal sinuses and hyperdense mass lesion (15 × 10 mm) in sellar, left parasellar and suprasellar region, extending up to 3rd ventricle (Fig. 1b, c) . CECT adrenal was normal. He underwent transfrontal pituitary adenomectomy followed by external beam radiotherapy (45 Gy) over six weeks. Immunostaining for GH on tumour tissue sections was positive and histopathology of bone lesion confirmed fibrous dysplasia. GH dynamics 3 months later showed high basal GH (72 ng/ml) with paradoxical rise (104 ng/ml) after glucose load. He refused to undergo resurgery because he could not afford medical treatment. In May 97, he presented in stuporose state due to bronchopneumonia and septicemia to which he succumbed.
Case 2
A 25-year-old man presented with progressively increasing multiple hard swellings over head and right half of the face for 15 years and retro-orbital headache and acral enlargement for last 2 years. He gave no history of visual disturbance, seizures, sexual dysfunction or any neural deficit. Onset and development of his secondary sex features were normal. On examination, his height was 161 cm, weight 71 kg, BMI 29 Kg/m 2 , BP 120/70 mmHg and was normally virilized (A3, P6, testicular volume of 20 ml). He had facial asymmetry with coarse features and acral enlargement with excessive sweating. He had no café-au-lait macules and goitre but had multiple, non-tender, bony swellings over right frontal and occipital regions of vault and right maxilla including the alveolar process. Systemic examination was normal.
On investigation, basal GH was 92 ng/ml that paradoxically rose to 350 ng/ml following 75 gm oral glucose. In response to 100 mg IV bolus TRH, GH increased from 85 ng/ml to 189 ng/ml. Serum PRL was 450 mIU/L, T 3 1.0 ng/ml, T 4 54 ng/ml and cortisol at 8 am 600 nmol/L and at 4 pm 300 nmol/L, LH 1.56 IU/L, FSH 1.25 IU/L and testosterone 8 nmol/L. X-ray skull showed radiodense lesions in frontoparietal bone and base of skull. CECT head revealed isodense sellar mass (20 × 10 mm) with suprasellar extension and ground glass lesions in skull bones and in maxilla. Long bones and pelvic skeletal survey did not reveal any other abnormalities. The typical findings of increased tracer uptake in skull bones and in maxilla but nowhere else on 99m T c methelyne diphosphonate (MDP) bone scan is shown in Fig. 1d . Fine needle aspiration cytology from maxillary lesion confirmed fibrous dysplasia. He underwent transfrontal adenomectomy uneventfully. Immunostaining on tumour tissue sections for GH was positive. GH dynamics 3 months later showed basal GH was 25 ng/ml and suppressed to 10 ng/ml after glucose load. He received prednisolone and testosterone replacement therapy and 45 Gy external beam irradiation over 6 weeks for residual tumour. He is well for the last 4 years with GH levels of 5 ng/ml after glucose load.
Case 3
A 19-year-old man presented with erectile dysfunction for last few months. He experienced progressive gain in height, and had headache and acral enlargement for last 4-5 years. He gave no history of visual symptoms, seizures or neural deficits. On examination, his height was 208 cm, weight 110 kg, BMI 25.4 Kg/m 2 and BP 130/90 mmHg. He had coarse facial features and acral enlargement with excessive sweating but no café-au-lait macules, bony swelling or goitre. Systemic examination was normal. He was poorly virilized (A 2 P 4 , testicular volume 12 ml with sparse facial hairs).
On investigation, his basal GH was 88 ng/ml and paradoxically rose to 130 ng/ml following 75 gm glucose. In response to 100 mg IV bolus TRH, GH increased from 78 ng/ml to 130 ng/ml. Serum PRL was 1150 mIU/L, T 3 0.9 ng/ml, T 4 40 ng/ml, cortisol at 8 am 330 nmol/L and at 4 pm 280 nmol/L, LH 2.1 IU/ml, FSH 1.25 IU/ml and testosterone 1.6 nmol/L. X-Ray skull showed radiodense lesions in base of skull, ethmoid and sphenoid bone and orbital plate with enlarged sella, while skeletal survey for other areas did not show any abnormalities. CECT head showed pituitary macroadenoma (21 × 30 mm) with suprasellar extension and ground glass appearance in above mentioned areas. He received L-thyroxine and prednisolone replacement therapy and underwent transfrontal pituitary adenomectomy. Immunostaining on tumor tissue sections for GH and PRL was positive. Histopathology of bone lesion confirmed fibrous dysplasia consisting of immature woven bone trabeculae characteristically lacking osteoblastic rim against a background of spindle cell stroma. The periphery of the tumour adjacent to uninvolved bone showed a rim of reactive new bone formation (Fig. 2) . GH dynamics 3 months later showed high basal GH (30 ng/ml) that was suppressed to 15 ng/ml after 75 gm glucose load. Serum PRL became normalized (600 mIU/L) and his adrenocortical reserve was normal. He is on L-thyroxine and testosterone replacement therapy and received 45 Gy external beam radiotherapy over 6 weeks for residual tumour. He is well for the last 2 years with GH levels of 10 ng/ml after glucose load. The clinical profile of these 3 patients is summarized in Table 1 .
Discussion
Two of the following lesions, namely poly/monostotic fibrous dysplasia, cutaneous pigmented macules and hypersecretory endocrinopathies are suffice to make the diagnosis of MAS [1, 2] . Two of our patients (case 1 and 3) had monostotic lesions and one (case 2) polyostotic (skull and maxilla) but none had café-au-lait macules. This is in contrast to all (51 patients) but eight of the reported patients who had café-au-lait macules and only four of them had monostotic lesions (Table 2 ). In almost every case, the base of the skull was involved as seen in all of our patients. However, the course of dysplastic bone disease is independent of the time of onset and degree of disease activity [3] .
No endocrine organ other than the pituitary was involved in our patients. This contrasts with the reported prevalence of sexual precocity (34%), thyrotoxicosis (11%) and hypercortisolism (3%) in patients with MAS associated with acromegaly [3] . Only one pa- tient of MAS with acromegaly and hyperthyroidism has been reported due to mixed somato-thyrotropinoma [30] . GH hypersecretion in MAS differs in several aspects from that observed in classical acromegaly. Patients are generally young (<20 years) at the onset and diagnosed on the basis of growth acceleration rather than facial dysmorphism which is usually difficult to assess due to fibrous dysplasia [3, 4] . Our patients had onset of disease around age 10 and two of them were acro-giants. Only half of the patients with MAS and acromegaly exhibit radiological evidence of pituitary adenoma compared with 80-90% in classical acromegaly [4] . Only 3 (17%) of 17 patients in the Cuttler et al. [21] series and 4 (33%) of 12 in Akintoye et al. [34] report had a pituitary mass with suprasellar extension. All of our patients had sellar mass with suprasellar extension and immunostaining for GH on tumor tissues was positive. Hyperprolactinemia was observed in only one of our patients in contrast to its reported prevalence of 85% in MAS with GH hypersecretion vis-à-vis 20-40% in classical acromegaly [3, 4] . Increase in serum GH after TRH is a consistent feature of MAS with acromegaly, while 70-80% of classical acromegaly have this response [3, 21] . All of our patients had rise in GH in response to TRH. GH dynamics during pregnancy in a patient with acromegaly with MAS has been reported recently [33] . It differs in its lack of autonomicity as compared to classic acromegaly with pregnancy where tumour behaviour is entirely autonomous [33] .
The pathogenesis of hypersecretory endocrinopathies in MAS involves post-zygotic activating mutation of the cAMP-regulating protein, GNAS 1 gene product Gsa, wherein arginine is replaced by other amino acids at position 201 [32, 33, 35] . This results in the constitutive activation of adenylate cyclase and the subsequent cAMP formation as a second messenger [33, 34] . However, functionally normal Gsa protein mutation in acromegaly with MAS has also been reported suggesting a defect beyond Gsa receptor [30] . Characteristically, cells that respond through ac- (2) + (4) - (1) Polyostotic (4) Monostotic (1) Acromegaly (5) HPRL (4) + (4 tivation of adenyl cyclase (cAMP system) are involved in hypersecretory endocrinopathies of MAS [33, 35] . Pituitary surgery in this syndrome is beset with problems mainly related to fibrous dysplasia and the resultant thickening of bones [3, 4, 19, 28] . Occasional instances of sarcomatous transformation of fibrous dysplastic bones have been reported with radiation therapy [18, 23] . Bromocryptine, cabergoline and long acting somatostatin analogue have been used with some success in acromegaly with MAS [3, 4, 28, 31, 33] . Our patients underwent transfrontal adenomectomy with partial removal of tumour. Two of them received megavoltage irradiation for residual tumours because of non-affordability for medical treatment and both are doing well.
